IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 07, 2025, titled "Press Release Financial Results for the quarter ended 30th June 2025".
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IOL Chemicals and Pharmaceuticals reported strong Q1 FY26 results with revenue from operations rising 9.8% year-on-year to ₹551.7 crore, up from ₹502.4 crore in Q1 FY25. EBITDA grew 19.5% to ₹69.5 crore with margins expanding by 102 basis points to 12.4%, reflecting better operating efficiency despite pricing pressures. Profit after tax increased 14.4% to ₹34.0 crore, while cash PAT rose 16% to ₹54.8 crore. Key operational updates include securing EU REACH registration for Acetic Anhydride, launching a ₹5.5 crore Minoxidil manufacturing unit expected by December 2025, and earning the EcoVadis Silver Medal for sustainability performance. Non-Ibuprofen APIs are operating at 65-70%+ utilization, indicating strong demand beyond the company's flagship product.
Broad-based growth across revenue, profitability, and margins signals healthy business momentum and operational leverage, likely to be viewed positively by investors. New regulatory approvals, capacity additions, and sustainability recognition support the long-term growth narrative, though investors should watch for sustained margin expansion and successful execution of the Paracetamol and Minoxidil projects.